Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

Table 4 Percentage of variation in Foxp3+Treg and lymphocyte count

	Foxp3+Tregs (%) before and after TMZ	All lymphocytes (%) before and after TMZ	Foxp3+Tregs after TMZ and IL-2	All lymphocytes (%) after TMZ and IL-2	Foxp3+Tregs before and after TMZ	Foxp3+Tregs after TMZ and IL-2	Basal Foxp3+Tregs (%) after IL-2	All basal lymphocytes (%) after IL-2
	1st cycle	1st cycle	1st cycle	1st cycle	4th cycle	4th cycle	4th cycle	4th cycle
All patients	− 60 . 5 p = 0 . 017	− 14 . 2 p = 0 . 020	+75.4	+15	−5.5	+38.6	−20.3	−4.0
DCR	−30.2	−11.9	−33.8	−22.2	−5.3	+53.2	−37.4	−16.4
PD	− 76 . 4 p = 0.032	−17.1	+388.9	+32.9	−22	+38.6	−20.3	+7.8

TMZ Temozolomide, IL-2, Interleukin-2, DCR Disease control patients, PD Progressive disease patients.

ISSN: 1479-5876